Sunlenca (lenacapavir) is a new type of antiretroviral medication. In late 2022, FDA (the U.S. Food and Drug Administration) approved Sunlenca, a new HIV drug for adults with limited treatment options. This drug is prioritized for the adult patients who are living with human immunodeficiency virus type 1 (HIV-1) and can’t successfully treat their HIV infections using other available treatment options due to resistance, intolerance, or safety reasons. Source: US FDA news release. Accessed 21/02/2023.
PharmaMedical Trend Analysis (PMTA)
Medical Pharmaceutical News